None listed
Conditions
Interventions
Drug : In randomization, 100 patients will proceed with Rochevastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.
A new generation of drug elution stents can be
Sponsors
Yonsei University Yongin Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 19 years of age or older 2. Patients who underwent a new generation of drug elution stent implantation for cardiovascular disease
Exclusion criteria
Exclusion criteria: 1. LDL cholesterol levels below 55 mg/dL without statin treatment 2. Serum AST/ALT with an acute liver disease within a month or a normal upper limit that is not continuously explained 3. Allergies or overreactions to statins 4. Estimated Dawn of Less than 1 Year 5. If it is determined that follow-up is not possible for more than one year 6. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of statins changed to discontinuation or intolerance (muscle pain, muscle efficiency, elevated liver level, etc.) within a year;Rate at which LDL cholesterol remains below 55 mg/dL in all 1-year blood tests | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate at which LDL cholesterol is maintained at 55 mg/dL in the blood test after a month;Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary artery re-perfusion;Each secondary evaluation variable;Newly developed diabetes, difficulty in controlling sugar,;occurrence of statin-related muscle symptoms requiring therapeutic or dose changes;Increased muscle enzyme aberration (CPK > 4 x normal upper limit);Elevated liver enzyme levels (AST, ALT, or both = 3 x normal upper bound);Elevated serum creatine levels (from >50% baseline);Major bleeding (BARC type 2, 3, or 5);Reason for discontinuation or intolerance | — |
Countries
Korea, Republic of
Contacts
Public ContactDeokKyu Cho
Yonsei University Yongin Severance Hospital
Outcome results
None listed